Bhasin S, Storer T W, Javanbakht M, Berman N, Yarasheski K E, Phillips J, Dike M, Sinha-Hikim I, Shen R, Hays R D, Beall G
Division of Endocrinology, Metabolism, and Molecular Medicine, Charles R. Drew University of Medicine and Science, Los Angeles, CA 90059, USA.
JAMA. 2000 Feb 9;283(6):763-70. doi: 10.1001/jama.283.6.763.
Previous studies of testosterone supplementation in HIV-infected men failed to demonstrate improvement in muscle strength. The effects of resistance exercise combined with testosterone supplementation in HIV-infected men are unknown.
To determine the effects of testosterone replacement with and without resistance exercise on muscle strength and body composition in HIV-infected men with low testosterone levels and weight loss.
Placebo-controlled, double-blind, randomized clinical trial conducted from September 1995 to July 1998 at a general clinical research center.
Sixty-one HIV-infected men aged 18 to 50 years with serum testosterone levels of less than 12.1 nmol/L (349 ng/dL) and weight loss of 5% or more in the previous 6 months, 49 of whom completed the study.
Participants were randomly assigned to 1 of 4 groups: placebo, no exercise (n = 14); testosterone enanthate (100 mg/wk intramuscularly), no exercise (n = 17); placebo and exercise (n = 15); or testosterone and exercise (n = 15). Treatment duration was 16 weeks.
Changes in muscle strength, body weight, thigh muscle volume, and lean body mass compared among the 4 treatment groups.
Body weight increased significantly by 2.6 kg (P<.001) in men receiving testosterone alone and by 2.2 kg (P = .02) in men who exercised alone but did not change in men receiving placebo alone (-0.5 kg; P = .55) or testosterone and exercise (0.7 kg; P = .08). Men treated with testosterone alone, exercise alone, or both experienced significant increases in maximum voluntary muscle strength in leg press (range, 22%-30%), leg curls (range, 18%-36%), bench press (range, 19%-33%), and latissimus pulls (range, 17%-33%). Gains in strength in all exercise categories were greater in men assigned to the testosterone-exercise group or to the exercise-alone group than in those assigned to the placebo-alone group. There was a greater increase in thigh muscle volume in men receiving testosterone alone (mean change, 40 cm3; P<.001 vs zero change) or exercise alone (62 cm3; P = .003) than in men receiving placebo alone (5 cm3; P = .70). Average lean body mass increased by 2.3 kg (P = .004) and 2.6 kg (P<.001), respectively, in men who received testosterone alone or testosterone and exercise but did not change in men receiving placebo alone (0.9 kg; P = .21). Hemoglobin levels increased in men receiving testosterone but not in those receiving placebo.
Our data suggest that testosterone and resistance exercise promote gains in body weight, muscle mass, muscle strength, and lean body mass in HIV-infected men with weight loss and low testosterone levels. Testosterone and exercise together did not produce greater gains than either intervention alone.
先前针对感染HIV男性补充睾酮的研究未能证明肌肉力量有所改善。抗阻运动与补充睾酮相结合对感染HIV男性的影响尚不清楚。
确定在睾酮水平低且体重减轻的感染HIV男性中,进行与不进行抗阻运动时补充睾酮对肌肉力量和身体成分的影响。
1995年9月至1998年7月在一家综合临床研究中心进行的安慰剂对照、双盲、随机临床试验。
61名年龄在18至50岁之间、血清睾酮水平低于12.1 nmol/L(349 ng/dL)且在过去6个月内体重减轻5%或更多的感染HIV男性,其中49人完成了研究。
参与者被随机分为4组中的1组:安慰剂组,不运动(n = 14);庚酸睾酮(每周100 mg,肌肉注射),不运动(n = 17);安慰剂与运动组(n = 15);或睾酮与运动组(n = 15)。治疗持续时间为16周。
比较4个治疗组之间肌肉力量、体重、大腿肌肉体积和去脂体重的变化。
仅接受睾酮治疗的男性体重显著增加2.6 kg(P <.001),仅进行运动的男性体重增加2.2 kg(P = .02),而仅接受安慰剂治疗的男性体重下降0.5 kg(P = .55),接受睾酮与运动治疗的男性体重增加0.7 kg(P = .08)。仅接受睾酮治疗、仅进行运动或两者兼有的男性在腿举(增幅范围为22% - 30%)、腿弯举(增幅范围为18% - 36%)、卧推(增幅范围为19% - 33%)和背阔肌下拉(增幅范围为17% - 33%)方面的最大自主肌肉力量均显著增加。在所有运动类别中,分配到睾酮 - 运动组或仅运动组的男性力量增加幅度大于分配到仅安慰剂组的男性。仅接受睾酮治疗的男性(平均变化40 cm³;与零变化相比,P <.001)或仅进行运动的男性(62 cm³;P = .003)大腿肌肉体积的增加幅度大于仅接受安慰剂治疗的男性(5 cm³;P = .70)。仅接受睾酮治疗或接受睾酮与运动治疗的男性平均去脂体重分别增加2.3 kg(P = .004)和2.6 kg(P <.001),而仅接受安慰剂治疗的男性去脂体重增加0.9 kg(P = .21)。接受睾酮治疗的男性血红蛋白水平升高,而接受安慰剂治疗的男性则未升高。
我们的数据表明,睾酮和抗阻运动可促进体重减轻且睾酮水平低的感染HIV男性增加体重、肌肉量、肌肉力量和去脂体重。睾酮与运动联合使用并不比单独任何一种干预措施产生更大的效果。